✦ LIBER ✦

The majority of patients with carcinoid syndrome prefer treatment with lanreotide,

Book ID: 120869894
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2000
Weight: 151 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200012320-00025

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of the carcinoid syndrome with

Treatment of the carcinoid syndrome with a depot formulation of the somatostatin analogue lanreotide

✍ Scherübl, H.; Wiedenmann, B.; Riecken, E.O.; Thomas, F.; Böhme, E.; Räth, U. 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 238 KB

Long-term results of treatment of malign

Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel)

✍ M. S. Khan; F. El-Khouly; P. Davies; C. Toumpanakis; M. E. Caplin 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 237 KB

Metabolic acidosis in patients with the

Metabolic acidosis in patients with the carcinoid syndrome: Treatment with parachlorophenylalanine

✍ Jerome M. Feldman 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 479 KB

Pre-treatment with somatostatin in the a

Pre-treatment with somatostatin in the anaesthetic management of a patient with carcinoid syndrome

✍ Winston C. V. Parris; John A. Oates; Jay Kambam; Richard Shmerling; John F. Sawy 📂 Article 📅 1988 🏛 Springer-Verlag 🌐 French ⚖ 305 KB

Sa1149 Possible Predictors of Patient-Re

Sa1149 Possible Predictors of Patient-Reported Satisfaction With Diarrhea Control Associated With Lanreotide Depot (LAN) Treatment for Carcinoid Syndrome (CS) in Gastroenteropancreatic Neuroendocrine Tumor (NET) Patients

✍ Ruszniewski, Philippe; Caplin, Martyn; Valle, Juan; Lombard-Bohas, Catherine; Po 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Treatment of carcinoid syndrome : A pros

Treatment of carcinoid syndrome : A prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance

✍ Dermot O'Toole; Michel Ducreux; Gilles Bommelaer; Jean-Louis Wemeau; Olivier Bou 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB

## BACKGROUND. The somatostatin analogues lanreotide and octreotide have previously been shown to be effective in controlling flushing and diarrhea in patients with carcinoid syndrome. As lanreotide requires injection only every 10 days, compared with twice-daily injections of octreotide, a direct